NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen

NLS Pharmaceutics (NASDAQ:NLSP) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

NLS Pharmaceutics Trading Down 5.1%

NLS Pharmaceutics stock opened at $2.44 on Friday. The firm’s 50 day moving average price is $2.08 and its two-hundred day moving average price is $1.91. NLS Pharmaceutics has a twelve month low of $1.30 and a twelve month high of $15.59.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).